Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

Cristina Baleriola, William Rawlinson, Gregory J Dore, Sandra Chaverot, Sacha Stelzer-Braid, Motoko Yoshihara, Darrell Crawford, William Sievert, Geoffrey McCaughan, Martin Weltman, Wendy Cheng, Bishoy Rizkalla, Dwight Dubois, James Thommes, Stuart Roberts

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMana?? HCV RNA assay (TaqMan) and Roche Cobas(A?) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia.
Original languageEnglish
Pages (from-to)173 - 180
Number of pages8
JournalAntiviral Therapy
Issue number2
Publication statusPublished - 2011

Cite this